These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 21883438)

  • 1. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
    Davies MJ; Chubb BD; Smith IC; Valentine WJ
    Diabet Med; 2012 Mar; 29(3):313-20. PubMed ID: 21883438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
    Tzanetakos C; Melidonis A; Verras C; Kourlaba G; Maniadakis N
    BMC Health Serv Res; 2014 Sep; 14():419. PubMed ID: 25245666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K; Persson U
    J Med Econ; 2014 Sep; 17(9):658-69. PubMed ID: 24950434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC; Conner C; Hammer M
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC; Samyshkin Y; Langer J; Palmer JL
    J Med Econ; 2012; 15 Suppl 2():28-37. PubMed ID: 22834986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
    Schwarz B; Gouveia M; Chen J; Nocea G; Jameson K; Cook J; Krishnarajah G; Alemao E; Yin D; Sintonen H
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():43-55. PubMed ID: 18435673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L; Zhao FL; Li SC
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
    Langer J; Hunt B; Valentine WJ
    J Manag Care Pharm; 2013 Apr; 19(3):237-46. PubMed ID: 23537458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
    Davies M; Pratley R; Hammer M; Thomsen AB; Cuddihy R
    Diabet Med; 2011 Mar; 28(3):333-7. PubMed ID: 21309842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
    Lee WC; Conner C; Hammer M
    Curr Med Res Opin; 2011 May; 27(5):897-906. PubMed ID: 21348806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
    Arechavaleta R; Seck T; Chen Y; Krobot KJ; O'Neill EA; Duran L; Kaufman KD; Williams-Herman D; Goldstein BJ
    Diabetes Obes Metab; 2011 Feb; 13(2):160-8. PubMed ID: 21199268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide for the treatment of type 2 diabetes.
    Shyangdan D; Cummins E; Royle P; Waugh N
    Health Technol Assess; 2011 May; 15 Suppl 1():77-86. PubMed ID: 21609656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
    Pratley R; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Garber A; Thomsen AB; Hartvig H; Davies M;
    Int J Clin Pract; 2011 Apr; 65(4):397-407. PubMed ID: 21355967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
    King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
    Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
    Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
    Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
    Arai K; Maeda H; Sirabe S; Yamamoto R; Yamauchi M; Hirao T; Hirao S; Hirao K
    Diabetes Technol Ther; 2013 Apr; 15(4):335-41. PubMed ID: 23480592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
    Nauck M; Frid A; Hermansen K; Thomsen AB; During M; Shah N; Tankova T; Mitha I; Matthews DR
    Diabetes Obes Metab; 2013 Mar; 15(3):204-12. PubMed ID: 22985213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of liraglutide in type II diabetes: a systematic review.
    Zueger PM; Schultz NM; Lee TA
    Pharmacoeconomics; 2014 Nov; 32(11):1079-91. PubMed ID: 25052903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.